NecstGen

What does it take to bring a cell or gene therapy to patients? Have you ever wondered what it means to develop viral vectors, cell therapies, (ex vivo) gene therapies, and more? Watch the video. Bringing a product from R&D to production takes work. When developing a cell therapy, for example, we very closely examine the processes that our client has developed so far. We go through them, identify the critical process steps, and adjust them to achieve a GMP-compliant manufacturing process. But what is the most critical aspect of it all? We operate at the edge of scientific discovery, always keeping the patient at the centre. NecstGen helps academic and industrial Cell and Gene Therapy developers enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC, and regulatory affairs in a 4,000 m2 development and GMP manufacturing facility. Watch the video and start exploring how we bring CGTs closer to the patients who need them. #celltherapy #genetherapy #viralvector #cdmo

Last Call: Join us at The CGT Circle Event hosted by NecstGen on October 16th dedicated to women in Cell & Gene Therapy! With only about 20 tickets left, this is your last chance to join an exclusive gathering of female leaders and innovators in Cell and Gene Therapy. Don’t miss out on the unique opportunity to hear from top experts on their career development and current activities, gather insights in how to improve your female communication skills, and expand your network. Highlighted Speakers: * Françoise Carlotti, Leiden University Medical Center – "Regenerative medicines for diabetes: iPSC-derived insulin-producing cells" * Maria Gomes Fernandes, PhD, Meatable – „"Be as plastic as a stem cell" - Transitioning from academia to industry“ * Rachel Abbott, Pan Cancer T – "Reflections on an unexpected career path from post-doc to CEO" * Ester Weijers, NTrans Technologies BV – "Embrace challenges – from MBO to CEO" * Veronique van de Sande, Communication and Leadership Trainer - „How to improve your female communication skills“ We look forward to welcoming you. 📍 Location: NecstGen, Leiden ⏰ Date and Time: October 16th, 4 PM ❗ Registration is closed. Contact Sophia, if you missed the opportunity to sign up. ❗:  https://lnkd.in/esu5-jTX

Last week, OogFarma and NecstGen signed a strategic partnership to enhance the safety and efficiency of ophthalmic therapies in the Netherlands. Through this collaboration, OogFarma will utilize NecstGen’s state-of-the-art GMP-compliant cleanrooms to support the distribution of anti-VEGF treatments vital for patients with macular degeneration. This partnership reflects our shared mission to make critical therapies more accessible and affordable. We’re working together to improve patient safety, streamline processes, and ultimately reduce healthcare costs by leveraging innovative, ready-to-use syringe systems. “NecstGen’s advanced facilities offered a true plug-and-play solution that meets all our needs, from quality control to essential training,” said Bart-Jan Thies, CEO of OogFarma. Read more about how we’re supporting OogFarma’s mission to deliver affordable and innovative ophthalmic treatments to healthcare providers: https://lnkd.in/eZ_r4mNQ #ophthalmology #atmp #celltherapy #biotech #innovation

Last Friday, Melissa Van Pel and Sophia Kolbe visited the Lund Stem Cell Center, where Melissa presented on "Translational Considerations for Your Future Cell Therapy Production Process". Her talk covered crucial aspects of process development, manufacturing, and quality control for iPSC-derived cell therapies. We thank everyone who attended and special appreciation to Elias Uhlin for organising this insightful visit and providing a platform to discuss these essential topics. It's inspiring to see Lund Stem Cell Center's commitment to ATMPs expanding ATMP development and infrastructure to support the translation of their ongoing advanced therapy programs into clinical applications— efforts that align closely with NecstGen's mission to advance cell and gene therapies from concept to clinic. We are eager to share our knowledge and experience and are looking forward to exploring future collaboration opportunities to support making these transformative therapies more accessible for patients in need. Interested in Lund University's latest ATMP activities? Click the link to have a look at Lund Stem Cell Center's 2024 ATMP pipeline report: https://lnkd.in/erj9WPSm #atmp #stemcells #celltherapy #genetherapy

Yesterday Sophia Kolbe presented and joined a panel discussion during a session on "Manufacturing and Automation in Cell Therapy Development" at the International Society for Stem Cell Research Copenhagen International Symposium on Pluripotent Stem Cell Derived Therapies, sharing and gaining insights into the future of cell therapy manufacturing. From exploring the use of automation to examining allogeneic vs. autologous manufacturing approaches, strategies to reduce costs, and the integration of AI-based tools, it was a rich discussion on how we can advance the field. Thank you to everyone who attended the session and panel discussion. Today is the last day of the conference. If you haven't already visited our stand, we invite you to stand #7 to talk about Cell and Gene Therapy and how NecstGen can support your cell therapy development and manufacturing needs— André Soares and Sophia Kolbe are looking forward to connecting with you! #ISSCR #stemcells #IPSC #celltherapy #GMP

Chimeric Antigen Receptor (CAR) T Cell Therapy offers a innovative approach in immunotherapy harnessing immune cells to target and eliminate target cells such as cancer cells.  But what critical steps ensure development of safe and efficacious therapies? The journey from discovery to clinical application begins with three critical steps: target identification, CAR design, and preclinical testing. Each stage plays a crucial role in developing safe and effective therapies. Whether you're involved in research, development, or clinical applications, understanding these early stages is crucial for success. We break down the first stages of CAR T cell therapy development, answering essential questions such as: - What are the critical steps in the development of CAR T cell therapy? - How is a target antigen selected for CAR T cell therapy, and why is it important? - What are the components of a Chimeric Antigen Receptor (CAR), and how do they function? - What methods are used to test the safety and efficacy of CAR T cells in preclinical development? - Why is preclinical testing essential before moving CAR T therapies into clinical trials? Are you curious to learn more about CAR T cell therapy?  Read the full blog here: https://lnkd.in/gspRwetf #immunotherapy #cartcelltherapy #biotech #oncology #research #celltherapy

We're enthusiastic to highlight our brilliant speakers, who are joining us for the upcoming The CGT Circle, hosted by NecstGen, on October 16th! The exciting lineup of female experts from academia and industry will cover various topics, from innovative research to leadership in the CGT industry. Swipe through the carousel to get a firsthand preview of what to expect!   • Françoise Carlotti, Associate Professor and Head of the Islet Research lab, Leiden University Medical Center "Regenerative medicines for diabetes: iPSC-derived insulin-producing cells" • Maria Gomes Fernandes, PhD, Head of Cell & Tissue Sciences, Meatable "Be as plastic as a stem cell" – transitioning from academia to industry • Rachel Abbott, CEO, Pan Cancer T "Reflections on an unexpected career path from post-doc to CEO" • Ester Weijers, CEO, NTrans Technologies BV Technologies "Embrace challenges – from MBO to CEO" • Veronique van de Sande, Communication and Leadership Trainer "How to improve your female communication skills"   Take the chance to engage with female thought leaders, network with peers, and explore new perspectives in the field of Cell & Gene Therapy.   Register here to attend the event: https://lnkd.in/esu5-jTX

From October 2nd – 4th, NecstGen will participate in the International Society for Stem Cell Research Copenhagen International Symposium on “PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success”. Join us for the session on “Manufacturing & Automation in Cell Therapy Development” on October 3rd, 3:15 PM – 5:00 PM in Queen’s Hall. During this session, at 4:25 PM, Melissa Van Pel will present an Innovation Showcase entitled “GMP-compliant Manufacturing of iPSCs and iPSC-derived Cell Therapies.” Melissa’s talk will focus on the rigorous processes involved in producing induced pluripotent stem cells (iPSCs), their use in Cell Therapy development, and Good Manufacturing Practice (GMP) -compliant manufacturing. It will explore the critical steps of establishing and maintaining GMP Master Cell Banks (MCBs) and Working Cell Banks (WCBs) to ensure the consistency, safety, and potency of iPSC lines. Additionally, the use of bioreactors for the scalable and controlled expansion of iPSCs will be discussed. Following her presentation, she will participate in the panel discussion on the future of manufacturing and automation in cell therapy development. We invite all attendees to visit us at Booth #7 to discuss how NecstGen’s expertise can support your cell therapy development. Melissa Van Pel, Sophia Kolbe, and André Soares are very much looking forward to connecting with you. #ISSCR #stemcells #iPSC #celltherapy #GMP

NecstGen is delighted to accelerate Cell & Gene Therapy development and manufacturing together with our partner bioMérieux. This collaboration enables us to further support CGT researchers and manufacturers in meeting the complex demands of these therapies.   Combining our expertise in CGT with bioMérieux’s testing portfolio including Endotoxin Testing Solutions, we’re helping to streamline processes, improve efficiency, and ultimately shorten the time to reach patients in need. Together, we aim to overcome key industry challenges like sample complexity while focusing on sustainability and GMP compliance.

We’re excited to invite you to the CGT Circle event on October 16th at NecstGen's Leiden site. This event is a unique opportunity to learn from women in Cell and Gene Therapy (CGT), exchange ideas, and expand your professional network. Join us from 16:00 onwards for an inspiring afternoon dedicated to empower women in CGT. With insightful presentations, a Q&A session, and networking drinks, this event offers a fantastic chance to network with like-minded women in the field. - “Regenerative medicines for diabetes: iPSC-derived insulin-producing cells” by Françoise Carlotti, Associate Professor and Head of the Islet Research Lab, Leiden University Medical Center - “Be as plastic as a stem cell" - transitioning from academia to industry” by Maria Gomes Fernandes, PhD, Head of Cell & Tissue Sciences, Meatable - “Reflections on an unexpected career path from post-doc to CEO” by Rachel Abbott, CEO, Pan Cancer T - “Embrace challenges – from MBO to CEO” by Ester Weijers, CEO, NTrans Technologies BV We'll close with an engaging session by communication and leadership trainer Veronique van de Sande on “How to improve your female communication skills”. This event is ideal for women at all career stages working in academia and industry dedicated to Cell & Gene Therapy. Don’t miss out on this opportunity—register through Eventbrite to secure your spot! We look forward to seeing you there! https://lnkd.in/esu5-jTX Thanks to Kate Fynes, Lindsey Clarke, and Nicola Ambler from The CGT Circle for giving us the opportunity to host! #network #celltherapy #genetherapy #biotech #lifesciences #healthcare Topx Network